Brii Bio joins the NIH grave­yard along­side GSK, Lil­ly af­ter flop­ping an­ti­body study in hos­pi­tal­ized Covid-19 pa­tients

Just a day af­ter Glax­o­SmithK­line and Vir Biotech­nol­o­gy’s Covid-19 an­ti­body fell flat in an NIH-spon­sored tri­al for hos­pi­tal­ized pa­tients, re­searchers have eject­ed an­oth­er ther­a­py from the study. Is this the death knell for mon­o­clon­al an­ti­bod­ies for those pa­tients?

An an­ti­body cock­tail from Brii Bio­sciences failed to show a trend to­ward clin­i­cal ben­e­fit in the NIH’s AC­TIV-3 tri­al, and as a re­sult, did not meet cri­te­ria for fur­ther en­roll­ment. As such, the NIH shut down the study sub­group eval­u­at­ing the pro­gram Thurs­day, which con­tains the two Brii an­ti­bod­ies dubbed BRII-196 and BRII-198.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER